4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) is the most potent nucleoside analog inhibitor of HIV reverse transcriptase (RT). It retains a 3′-OH yet acts as a chain-terminating agent by diminishing translocation from the pretranslocation nucleotide-binding site (N site) to the posttranslocation primer-binding site (P site). Also, facile misincorporation of EFdA-monophosphate (MP) results in difficult-to-extend mismatched primers. To understand the high potency and unusual inhibition mechanism of EFdA, we solved RT crystal structures (resolutions from 2.4 to 2.9 Å) that include inhibition intermediates (i) before inhibitor incorporation (catalytic complex, RT/DNA/EFdA-triphosphate), (ii) after incorporation of EFdA-MP followed by dT-MP (RT/DNA EFdA-MP P •dT-MP N), or (iii) after incorporation of two EFdA-MPs (RT/DNA EFdA-MP P •EFdA-MP N); (iv) the latter was also solved with EFdA-MP mismatched at the N site (RT/DNA EFdA-MP P •EFdA-MP *N). We report that the inhibition mechanism and potency of EFdA stem from interactions of its 4′-ethynyl at a previously unexploited conserved hydrophobic pocket in the polymerase active site. The high resolution of the catalytic complex structure revealed a network of ordered water molecules at the polymerase active site that stabilize enzyme interactions with nucleotide and DNA substrates. Finally, decreased translocation results from favorable interactions of primer-terminating EFdA-MP at the pretranslocation site and unfavorable posttranslocation interactions that lead to observed localized primer distortions.
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EFdA | HIV-1 reverse transcriptase | inhibitors | NRTIs | X-ray crystallography H IV reverse transcriptase (RT) converts viral genomic RNA into viral DNA, which can then be integrated into the host genome. Most clinically used drugs that block HIV replication targeting RT are nucleoside RT inhibitors (NRTIs) that inhibit further DNA polymerization. Once incorporated into the viral DNA, NRTIs act as chain terminators due to the lack of a 3′-OH. Although current NRTIs are highly effective, treatment adherence often leads to the development of drug-resistant HIV variants. New and even more potent antiretrovirals are needed, especially drugs effective against current clinically significant drug-resistant HIV strains.
The most potent nucleoside analog antivirals possess 3′-OH groups. Entecavir is the most potent anti-hepatitis B NRTI drug, and sofosbuvir is the most successful anti-hepatitis C virus nucleotide drug (1) (2) (3) (4) (5) . 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) extends this concept as an anti-HIV agent. EFdA is a deoxyadenosine (dA) analog with 3′-OH, 4′-ethynyl (4′-E), and 2-fluoro (2-F) groups (Fig. 1) . EFdA blocks HIV replication in peripheral blood mononuclear cells (PBMCs) at picomolar concentrations, making it orders of magnitude more potent than current clinical anti-HIV NRTIs (6) (7) (8) . Recent phase I clinical data with EFdA (also known as MK-8591) demonstrate that it is well tolerated in healthy adult subjects (9) . Moreover, it has exceptionally favorable pharmacokinetic properties and an unusually long intracellular half-life compared with other NRTIs, mainly due to its resistance to degradation by adenosine deaminase (6, (9) (10) (11) (12) . Hence, it is targeted for use as a single 10-mg dose for >7 d (9) . Remarkably, ongoing studies with slow release parenteral formulations suggest the potential for a single injection to provide coverage for durations up to 1 y (9).
EFdA is effective against wild-type and clinical drug-resistant HIV strains (6) , and acts synergistically with the second-generation nonnucleoside RT inhibitor rilpivirine (13) . EFdA blocks simian immunodeficiency virus replication in vitro in macaque PBMCs better than tenofovir (TFV), zidovudine (AZT), and emtricitabine (FTC) (14) . In vivo, EFdA outperforms Truvada (a two-NRTI combination) in several humanized mouse models for HIV infection (12) . EFdA was highly effective at treating simian immunodeficiency virus-infected macaques with advanced AIDS. Furthermore, no toxicities have been noted in animals treated with EFdA (12, 14) .
Biochemical data indicate that, depending on the context of template sequence, EFdA can act either as a de facto immediate chain Significance 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA), a potent antiviral with an unusually long half-life, is currently in phase I clinical trials. It inhibits reverse transcriptase (RT) through a mechanism of action different from all approved anti-HIV drugs: After incorporation in the nascent DNA chain, it suppresses the rate of viral replication by diminishing RT translocation on the nucleic acid substrate. Here, we present four crystal structures of various inhibition intermediates. The structures provide insight into the structural basis of the unusual mechanism of inhibition and the exceptional potency of this promising antiviral.
terminator (ICT) or as a delayed chain terminator (DCT) that allows incorporation of a single nucleotide following EFdA-monophosphate (MP) and slows nucleotide extension after incorporation into the nascent primer (15) . Moreover, RT misincorporates EFdA-MP more efficiently than dA-triphosphate (TP), resulting in mismatched primers that are difficult to extend. Finally, when EFdA acts as a DCT, EFdA-MP-terminated primers are protected from the phosphorolytic excision that can lead to NRTI resistance (15) .
To determine the structural mechanisms of HIV inhibition by EFdA, we solved crystal structures that include intermediates of the RT inhibition reaction (Fig. 2) . The first structure is a precatalytic complex of RT bound to a dideoxyguanosine (ddG)-terminated double-stranded DNA and to incoming EFdA-TP (RT/DNA ddG-MP P/EFdA-TP, 2.4-Å resolution; Figs . This structure provides insight into why RT favors EFdA-MP misincorporation and why EFdA-misincorporated primers are difficult to extend.
Results and Discussion
RT/DNA ddG-MP P/EFdA-TP is the highest resolution structure (2.4 Å) of HIV-1 RT in complex with DNA and a nucleotide TP to date. This resolution enables reliable modeling of ordered water molecules at the polymerase active site. We observed two divalent metals bound at the polymerase active site (Fig. S1 ). Metal ion B, also known as a structural metal, is coordinated in an octahedral geometry, bound by the side chains of D110 and D185, the main chain carbonyl of V111, and three oxygen atoms from the α, β, and γ phosphates of the incoming nucleotide triphosphate (Fig. S1 ). Due to lack of 3′-OH group in the dideoxyguanosine monophosphate (ddG-MP) at P site, the coordination of magnesium ion A (known as a catalytic metal) is incomplete and likely low occupancy (Fig.  S1 ). The structure shows strong electron density for the 4′-E, 3′-OH, and 2-F of EFdA-TP, and reveals interactions of the incoming inhibitor at the N site ( Fig. 3 and Fig. S2 ). The 4′-E of EFdA-TP is bound at a preformed hydrophobic pocket defined by conserved residues A114, Y115, F160, and M184, and the aliphatic part of D185 (Fig. 4A) . Such extensive interactions of EFdA-TP at the N site are consistent with the previously reported high k on and low k off rates that result in RT binding EFdA-TP even better than dNTP substrates (15) . These interactions contribute to the inhibition mechanism of EFdA-TP as an ICT or translocation-defective RT inhibitor as they would favor binding of the EFdA-MP-terminated primer at the pretranslocation N site.
A unique feature of EFdA-TP compared with clinical anti-HIV NRTIs is its 3′-OH, which interacts through a hydrogen bond with the β-phosphate of the inhibitor (Fig. 4B and Fig. S2 ). This interaction is further stabilized by ordered water W 1 , which in turn is held in position by conserved protein backbone atoms of A114, Y115, and F116 (Fig. 4B) . We propose that NRTIs that lack a 3′-OH (such as dideoxynucleosides, AZT, d4T, 3TC, tenofovir, and abacavir) are less efficient in (i) conformationally stabilizing and optimally positioning the α-phosphate of the nucleotide substrate for nucleophilic attack by the primer 3′-OH, and (ii) stabilizing the pyrophosphate leaving group. Thus, the presence of a 3′-OH in EFdA-TP allows more efficient incorporation of the inhibitor into the viral DNA. In addition to the previously reported interactions of RT with the α, β, and γ phosphates of the incoming nucleotide [K65, R72, main-chain V111, D113, and Q151 (16)], improved resolution and good-quality electron density allowed assignment of additional interactions of K220 with the γ-phosphate (Fig. S3) . We also report another previously undescribed network of water molecules, which includes interactions between ordered waters W 2 and W 3 , the 2-F of EFdA-TP at the N site, the Y115 hydroxyl, the G152 main-chain amide and minor groove atoms of the nucleotide dG-dC base pair at the P site. dG-dC-specific interactions at the P site (with the 2-amino of dG and 2-carbonyl of dC; Fig. 4C ) may further stabilize pretranslocation complexes and explain the reported preference for the ICT rather than DCT mechanism of inhibition for such nucleic acid substrates (15) .
The RT/DNA EFdA-MP P •dT-MP N and RT/DNA EFdA-MP P •EFdA-MP N structures have EFdA-MP at only the P or at both the P and N sites (Figs. 2 B and C, and 5) . As in RT/DNA ddG-MP P/EFdA-TP, the 4′-E at the N site of RT/DNA EFdA-MP P •EFdA-MP N engages RT through strong hydrophobic interactions (Fig. 5C) .
To assess the role of 4′-E at the P site, we compared structures with EFdA-MP (Fig. 5B) or RT/DNA ddG-MP P/EFdA-TP (Fig. 5A) (17) . AZT is a thymidine analog with a 3′-azido group replacing the 3′-OH. The 3′-azido interaction is not through the hydrophobic pocket but through residues A114, Y115, and F116. These comparisons suggest that a 1.6-Å shift of EFdA-MP P is required to relieve the potential steric clash between the 4′-E of EFdA-MP P and the main-chain carbonyl of Y183 ( Fig. 5 A and  B) . Without such shift, the 4′-E − Y183 distance would be a highly unfavorable 1.7 Å (3.3 − 1.6 = 1.7 Å). Interestingly, the primer distortion is restricted to EFdA-MP at the P site and is not present upstream or downstream of EFdA-MP P (Fig. 5) . It is concurrent with a change in the EFdA-MP P γ-torsion dihedral angle (O4′-C4′-C5′-O5′; Fig. S4 ), which differs significantly from the γ-angle of other nucleotides at the P site (by up to j−66j + j+97j = 163°; Fig. S4A vs. Fig. S4B ; Table S1 ). The difference in γ-angle is not an inherent property of EFdA-MP, as the γ-angle of EFdA-MP N is different from that of EFdA-MP P and similar to that of nucleotides other than EFdA-MP bound at the P site (Fig. S4C vs. Fig. S4B , Table S1 ). Notably, the changed γ-torsion affects an interphosphate distance at the polymerase active site, from ∼5.8 Å (typical A DNA distance) to 6.9 Å (closer to B DNA; Fig. 5D ), which may also affect the translocation and DNA-binding properties of RT.
These findings provide structural insights regarding the ICT and DCT inhibition mechanisms: in the case of ICT, we propose that strong interactions of RT with EFdA-MP N prevent translocation of (17)]. In both A and B, without the localized 1.6-Å primer shift (marked dotted arrow) of EFdA-MP P , the currently observed 3.3-Å distance between the 4′-E and main-chain carbonyl of Y183 would have been highly unfavorable at ∼1.7 Å. This shift is accomplished through a change in the γ-torsion angle about the C4′-C5′ (Fig. S6A vs. Fig. S6B ; Table S1 ). ; in this case, we propose that inhibition occurs because of steric crowding between the 4′-E of EFdA-MP and the main chain of Y183, leading to localized primer distortions (Fig. 5 A and B) that may affect the translocation efficiency and DNA-binding properties of RT.
Moreover, further translocation of a DNA EFdA-MP P •dN-MP N placing the EFdA-MP at the "P-1" upstream primer site, would likely result in similar steric clashes between the 4′-E of EFdA-MP P-1 with the main chain of M230, as shown in the molecular model of RT/DNA EFdA-MP P-1 •dN-MP P (Fig. S5) . Thus, steric interactions of the 4′-E of EFdA-MP P or EFdA-MP P-1 with RT residues prevent further dN-MP additions, leading to DCT inhibition of DNA synthesis.
We previously demonstrated that the type of mechanism by which EFdA inhibits RT (ICT vs. DCT) is not stochastically determined but appears to depend on the template sequence in a complex and poorly understood manner. Our present structural data suggest that sequence-dependent differences in the observed interactions of 2-F, W 2 , and the base pair at the P site (Fig. 4C ) may affect the inhibition mechanism (ICT vs. DCT), along with other possible changes imposed by global curvature and flexibility of the nucleic acid.
Our previous biochemical studies suggested that EFdA can also inhibit HIV RT via facile misincorporation into nascent primers that are subsequently difficult to extend (15) . We confirmed this finding in primer extension assays shown in Fig. S6 using template/primers with the same sequence used in the crystallization studies. To elucidate the structural details of EFdA mismatch incorporation, we solved the RT/DNA EFdA-MP P •EFdA-MP *N structure that has EFdA-MP P extended by a mismatched second EFdA-MP against dA-MP at the N site (Fig. 2D) . The structure shows that EFdA-MP* N interacts with the "flipped" purine of dA-MP through Hoogsteen base pairing (Fig. 6) . In addition, the interaction of EFdA-MP with G152 through 2-F (Fig. 6) would be absent in a dA-MP•dA-MP mismatch. This may address why the EFdA-MP•dA-MP mismatch is more efficiently formed than the dA-MP•dA-MP mismatch (15) . Moreover, the strong interactions of EFdA-MP at the pretranslocation site through its 4′-E, 2-F, and 3′-OH groups, even when paired with a mismatched template base, may explain the inefficient extension of EFdA-MP* N (Fig. S7 ). In conclusion, our crystal structures provide the structural basis for understanding the EFdA inhibition mechanism and illuminate the roles of its three structural motifs, 4′-E, 3′-OH, and 2-F.
Regarding 4′-E, it is observed in all inhibition intermediate structures to consistently and extensively interact with conserved residues of an active-site hydrophobic pocket. To our knowledge, EFdA is the first antiviral exploiting this site, leading to a previously unidentified inhibition mechanism (Fig. 4A) . In addition, the 4′-E distorts the primer structure (Fig. 5 A-C) , thus altering the translocation and DNA-binding properties of RT. Regarding 3′-OH, it is a unique feature among NRTIs that significantly enhances antiviral potency (EFdA has 10,000 times higher antiviral activity than EFddA, the otherwise identical nucleoside lacking a 3′-OH) (7) . We propose this is due to improved binding and catalytic incorporation into the viral DNA (Fig. 4B) ; also, the 3′-OH of EFdA contributes to its rapid and facile activation by the deoxycytidine kinase (6, 18) . Finally, regarding 2-F, it contributes to improved inhibitor binding at the polymerase active site (Fig. 4C) and it provides exceptional resistance to adenosine deaminase-catalyzed degradation in cells (6, 11) . Remarkably, a single 10-mg dose of EFdA resulted in consistent viremia control for up to 10 d (9), offering exceptional promise for further development as an anti-HIV drug.
Materials and Methods
Protein Expression and Purification. BL21(DE3)-RIL cells containing two vectors carrying the p66 and p51 subunits of HIV-1 RT were expressed in LB and induced with 1 mM isopropyl β-D-1-thiogalactopyranoside at OD 600 of ∼0.6-0.8, followed by expression at 37°C for 3 h. Cell pellets were treated with lysozyme, homogenization, and sonication. RT was purified by nickel-affinity chromatography (GE Healthcare), followed by Mono Q anion exchange (GE Healthcare), and size-exclusion chromatography (Shodex) as previously described (15) . Fractions with pure RT were concentrated and stored at −80°C.
Crystallization of the RT/DNA Complex. We used a primer strand that contained a thioalkyl-tethered guanosine at the seventh position from the 3′-end, which was covalently cross-linked to RT Q258C through formation of a disulfide bond (Fig. 2 ) (19) . Double-stranded DNA was prepared with template sequence 5′-ATG GTC GGC GCC CGA ACA GGG ACT GTG-3′; 5′-ATG GAT GGC GCC CGA ACA GGG ACT GTG-3′; 5′-ATG GTT GGC GCC CGA ACA GGG ACT GTG-3′; 5′-ATG GAT GGC GCC CGA ACA GGG ACT GTG-3′ for RT/DNA ddG-MP P/EFdA-TP ternary complex, RT/DNA EFdA-MP P •dT-MP N and RT/DNA EFdA-MP P •EFdA-MP N binary complexes, and RT/DNA EFdA-MP P •EFdA-MP *N mismatched binary complex, respectively. The primer sequence used in all four structures was 5′-ACA GTC CCT GTT CGG G*CG CC-3′ (G* has a thioalkyl tether covalently attached to the N 2 group of the guanosine; Fig. 2 ) (Trilink Biotechnologies). Template and primer were first annealed at 95°C for 5 min, cooled at room temperature for 20 min, and stored at −20°C. The 15 μM annealed template/primer (T/P) substrates were incubated with 7 μM cross-linkable HIV RT in 25 mM Tris, pH 8.0, 100 mM NaCl, 10 mM MgCl 2 , and 0.1 mM 2′,3′-dideoxyguanosine-5′-triphosphate (ddG-TP) (GE Health Life Science) to obtain the RT/DNA ddG-MP P complex; 70 μM EFdA-TP and 0.1 mM deoxythymidine monophosphate (dT-MP) for the RT/DNA EFdA-MP P •dT-MP N binary complex; or 70 μM EFdA-TP for the RT/DNA EFdA-MP P •EFdA-MP N and RT/DNA EFdA-MP P •EFdA-MP *N complexes at 31°C for 18 h. Cross-linked RT-dsDNA complex was purified using a Ni-Heparin tandem column strategy (20) . Cross-linking efficiency was judged by an increase in the molecular weight of the p66 subunit in nonreducing SDS/PAGE. Fractions containing DNA-cross-linked RT were pooled and concentrated to 15.5 mg/mL. For the RT/DNA ddG-MP P/EFdA-TP ternary complex, initial RT/DNA ddG-MP P complex sample was incubated on ice for 15 min with 1.5 molar excess of EFdA-TP and 5 mM MgCl 2 . Hanging drops were prepared by mixing 1:1, 2:1, or 2:1 volume ratio of well solution and ternary complex. Crystals were grown at 18°C in 8% (wt/vol) PEG 4000, 25 mM Mes, pH 6.0, and 5 mM magnesium sulfate. Crystals were dehydrated by elevating PEG 4000 up to 35% (wt/vol) over 1 h and were flashcooled in liquid nitrogen.
Data Collection and Structure Determination. Data were collected on a CMOS detector at Advanced Light Source (ALS) beamline 4.2.2, Lawrence Berkeley National Laboratory (Table S2 ). Datasets were processed using XDS (21) and indexed in C222 1 (a = 167.5 Å, b = 169.8 Å, and c = 101.9 Å) with one complex per asymmetric unit. Crystal structures were solved by molecular replacement using PHASER (22) within the CCP4 package (23) . The Protein Data Bank (PDB) ID 3KK1 structure was used as a starting model. Several rounds of manual rebuilding using Coot (24) and refinement with the PHENIX package (25) were performed. Coordinates and molecular topologies for EFdA-TP and EFdA-MP were generated in SYBYL (https://www.certara.com/software/molecular-modelingand-simulation/sybyl-x-suite/) and PHENIX eLBOW (26) . The positions of EFdA-TP, EFdA-MP, or dT-MP in the structure were built into difference Fourier maps calculated before inclusion of the respective structural elements in refinement. Final atomic coordinates and structure factors have been deposited in the PDB (PDB ID: RT/DNA ddG-MP P/EFdA-TP, 5J2M; RT/ DNA EFdA-MP P •dT-MP N, 5J2N; RT/DNA EFdA-MP P •EFdA-MP N, 5J2P; RT/DNA EFdA-MP P •EFdA-MP* N, 5J2Q). The figures showing structural information were generated in PyMOL (www.pymol.org/).
RT Primer Extension Assay. The gel-based inhibition assay of HIV-1 RT-catalyzed DNA synthesis by EFdA-TP was carried out using 5′-Cy3-labeled DNA primer and an unlabeled template. To monitor primer extension, the 20 nM DNA/DNA was incubated at 37°C with 20 nM RT in buffer (50 mM NaCl, 50 mM Tris·HCl, pH 7.8). Varying amounts of EFdA-TP were added, and the reactions were initiated by the addition of 6 mM MgCl 2 in a final volume of 20 μL. The reactions were terminated after 3 h by adding an equal volume of 100% formamide containing traces of bromophenol blue. The products were resolved on a 15% polyacrylamide and 7 M urea gel and analyzed as previously described (15) .
